Alteogen signs deal with Novartis worth up to 4.4 tln won for subcutaneous formulations
--------------------------------------------------------------------
Source: South Korea
Published: 2026-09-02 16:49 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: South Korea, Technology
--------------------------------------------------------------------
Snippet:
SEOUL, Sept. 2 (Yonhap) -- South Korean biotechnology company Alteogen Inc. said Wednesday that it signed an option and licensing agreement with Novartis AG worth up to 4.4 trillion won (US$3.2 billion) to develop and commercialize subcutaneous (SC) formulations using its ALT-B4 technology.
--------------------------------------------------------------------